Unum Therapeutics Inc. (UMRX) Reaches $14.07 After 4.00% Down Move; Tableau Software (DATA)’s Sentiment Is 1.69

June 21, 2018 - By Stephen Andrade

Tableau Software, Inc. (NYSE:DATA) Logo

The stock of Unum Therapeutics Inc. (NASDAQ:UMRX) is a huge mover today! The stock decreased 9.63% or $1.5 during the last trading session, reaching $14.07. About 215,073 shares traded or 9.30% up from the average. Unum Therapeutics Inc. (NASDAQ:UMRX) has 0.00% since June 21, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical UMRX News: 03/04/2018 Unum Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with Seattle GeneticsThe move comes after 6 months negative chart setup for the $419.84M company. It was reported on Jun, 21 by Barchart.com. We have $13.51 PT which if reached, will make NASDAQ:UMRX worth $16.79 million less.

Tableau Software Inc (DATA) investors sentiment increased to 1.69 in 2018 Q1. It’s up 0.06, from 1.63 in 2017Q4. The ratio is positive, as 135 investment professionals increased or started new stock positions, while 80 decreased and sold their stock positions in Tableau Software Inc. The investment professionals in our database reported: 64.08 million shares, down from 65.34 million shares in 2017Q4. Also, the number of investment professionals holding Tableau Software Inc in top ten stock positions increased from 4 to 5 for an increase of 1. Sold All: 24 Reduced: 56 Increased: 77 New Position: 58.

Another recent and important Unum Therapeutics Inc. (NASDAQ:UMRX) news was published by Benzinga.com which published an article titled: “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” on June 20, 2018.

Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company has market cap of $419.84 million. The Company’s lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. It currently has negative earnings. The company's product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers.

Analysts await Unum Therapeutics Inc. (NASDAQ:UMRX) to report earnings on August, 13. After $-0.66 actual EPS reported by Unum Therapeutics Inc. for the previous quarter, Wall Street now forecasts -50.00% EPS growth.

The stock decreased 2.37% or $2.47 during the last trading session, reaching $101.66. About 267,568 shares traded. Tableau Software, Inc. (DATA) has risen 53.64% since June 21, 2017 and is uptrending. It has outperformed by 41.07% the S&P500. Some Historical DATA News: 27/03/2018 United Nations Establishes Tableau as Visual Analytics Standard, Streamlines Global Adoption of Platform; 02/05/2018 – TABLEAU 1Q ADJ LOSS/SHR 19C, EST. LOSS/SHR 18C; 02/05/2018 – Tableau Software 1Q Rev $246.2M; 07/05/2018 – Tableau Presenting at JPMorgan Conference May 15; 14/05/2018 – Tableau Presenting at JPMorgan Conference Tomorrow; 03/05/2018 – TABLEAU SOFTWARE INC DATA.N : WEDBUSH RAISES TARGET PRICE TO $104 FROM $100; 02/05/2018 – TABLEAU 1Q REV. $224.0M, EST. $217.9M; 03/05/2018 – TABLEAU SOFTWARE INC DATA.N : CITIGROUP RAISES TARGET PRICE TO $107 FROM $97; 16/05/2018 – Tableau at Non-Deal Roadshow Hosted By Bernstein AB Today; 30/04/2018 – Tableau Appoints Mark Nelson as Executive Vice President of Product Development

Analysts await Tableau Software, Inc. (NYSE:DATA) to report earnings on August, 1. They expect $-0.67 EPS, down 24.07% or $0.13 from last year’s $-0.54 per share. After $-0.73 actual EPS reported by Tableau Software, Inc. for the previous quarter, Wall Street now forecasts -8.22% EPS growth.

More important recent Tableau Software, Inc. (NYSE:DATA) news were published by: Gurufocus.com which released: “Four Jim Simons Stocks to Avoid or Sell” on June 21, 2018, also Seekingalpha.com published article titled: “Tableau Still Lacks Leverage”, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For June 20, 2018” on June 20, 2018. More interesting news about Tableau Software, Inc. (NYSE:DATA) was released by: Seekingalpha.com and their article: “This May Be The Scariest IPO Filing You’ve Ever Seen” with publication date: June 04, 2018.

Tableau Software, Inc. provides business analytics software products. The company has market cap of $8.29 billion. It offers Tableau Desktop, a self-service analytics product that empowers people to access and analyze data independently; and Tableau Server, a business intelligence platform with data management and scalability to foster sharing of analytics, as well as to improve the dissemination of information across an organization and promote improved decision-making. It currently has negative earnings. The firm also provides Tableau Online, a hosted SaaS version of Tableau Server; and Tableau Public, a cloud platform that allows users of various backgrounds, such as bloggers, journalists, researchers, and government workers to visualize public data on their Websites.

Hmi Capital Llc holds 15.9% of its portfolio in Tableau Software, Inc. for 1.36 million shares. Altimeter Capital Management Lp owns 3.35 million shares or 13.43% of their US portfolio. Moreover, Sheffield Asset Management L.L.C. has 13.2% invested in the company for 377,161 shares. The New York-based Cadian Capital Management Lp has invested 7.58% in the stock. Jericho Capital Asset Management L.P., a New York-based fund reported 924,457 shares.

Tableau Software, Inc. (NYSE:DATA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts